Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells
- 1 April 2015
- journal article
- Published by Elsevier in Cellular Signalling
- Vol. 27 (4) , 807-817
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Trade, Industry and Energy
- National Research Foundation of Korea
- Ministry of Education, Science and Technology (10035562, NRF-2013R1A1A2A100005494)
This publication has 35 references indexed in Scilit:
- The effectiveness of the oncolytic activity induced by Ad5/F35 adenoviral vector is dependent on the cumulative cellular conditions of survival and autophagyInternational Journal of Oncology, 2013
- TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complexCellular Signalling, 2013
- Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-κB Signaling Pathway in Human Pancreatic Ductal AdenocarcinomaInternational Journal of Molecular Sciences, 2012
- Overcoming drug resistance in pancreatic cancerExpert Opinion on Therapeutic Targets, 2011
- A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer ModelMolecular Cancer Therapeutics, 2010
- Pancreatic CancerNew England Journal of Medicine, 2010
- Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucinBritish Journal of Cancer, 2009
- c-Fos as a Proapoptotic Agent in TRAIL-Induced Apoptosis in Prostate Cancer CellsCancer Research, 2007
- Molecular Evidence for Increased Antitumor Activity of Gemcitabine by Genistein In vitro and In vivo Using an Orthotopic Model of Pancreatic CancerCancer Research, 2005
- Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma CellsClinical Cancer Research, 2004